LLY241213P750000
- 0.01
- 0.000.00%
Eli Lilly and Co Newsroom
CICC: Maintains innovent bio's 'outperform industry' rating, target price of 58 Hong Kong dollars.
CICC released a research report stating that it maintains the 'Outperform Industry' rating for INNOVENT BIO (01801), keeping the revenue and net income forecasts for 2024 largely unchanged. Considering the revenue from the initial payment brought by this authorization, it raises the 2025 revenue forecast by 5.4% to 10.986 billion yuan, while keeping the 2025 net income forecast at 0.495 billion yuan unchanged. It introduces the 2026 revenue forecast of 13.001 billion yuan and the net income forecast of 1.278 billion yuan. The target price is 58 HKD. On January 2, 2025, INNOVENT BIO announced a global exclusive cooperation licensing agreement with Roche, granting Roche the development rights.
Eli Lilly's (NYSE:LLY) Dividend Will Be Increased To $1.50
Novo Nordisk Seeks to Block Compounded Victoza
Santa Clause Came and Went Without Bringing Gifts | Weekly Buzz
Friday? More Like Grinch Day | Wall Street Today
Smart Money Is Betting Big In LLY Options
Viking Therapeutics Among Potential Buyout Candidates: Oppenheimer
Santa Claus Came Without Rallying the Troops | Live Stock
Jim Cramer Says Lazard Is 'Really Inexpensive,' Recommends Buying This Tech Stock
Eli Lilly and Company (LLY) Is Attracting Investor Attention: Here Is What You Should Know
Eli Lilly Joins FDA Lawsuit Over Compounded Obesity Drugs, Seeks 'Swift End' And 'To Protect Its Interests'
The 15.92% Average Gain in Inauguration Year: Will Trump's Second Term Echo the Trend?
Don't Buy Weight-Loss Medication From Unauthorized Sources, UK Health Agency Warns About Risks
Weight Loss Drugs Can Cut Grocery Spending by up to 9%: Study
Insurance is not covered, supply shortages, rampant generic drugs, slow new drug development, and new weight-loss medications still face challenges.
New GLP-1 weight loss drugs are not only changing the lives of obese populations but also creating billions of dollars in revenue for pharmaceutical companies like Eli Lilly and Co and Novo-Nordisk A/S. However, analysis indicates that weight loss drugs currently face some challenges in the USA: there is the risk of insurance companies refusing to pay, and ongoing supply shortages have created opportunities for lower-priced generic drugs. Additionally, it remains uncertain whether pharmaceutical companies can truly develop better weight loss medications and what the new U.S. government's attitude toward weight loss drugs will be.
Jefferies Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $994
Eli Lilly Stock Upgraded to "Buy" as Analysts Boost Price Target to $1,250
US Employer Health Costs To Rise In 2025 Fueled By Weight Loss: Report
The three major US stock index futures rose collectively, and all seven giants were up in pre-market trading | Highlights for tonight.
① NVIDIA GB300 may be released in the second quarter of 2025; ② Eli Lilly and Co's weight loss drug tirzepatide has officially launched in China; ③ Apple announces price reductions.
Eli Lilly and Co (LLY.US) officially announced the launch of Mufangda (Tirzepatide) in China.
On January 2, 2025, Eli Lilly and Co announced the official launch of Mufengda (Teriparatide Injection) in China, covering two indications.